Pfizer Canada Major Depressive Disorders Research Award (Grant)


Eligible Areas of Research: The focus of your research proposal must be in line with any of the following areas of research:

  • Explore efficacy of desvenlafaxine in subpopulations of patients, including co-morbid conditions
  • Research assessing the benefits of desvenlafaxine functionality in depressed patients in primary care settings
  • Exploring the adherence issues of antidepressant treatment in primary care settings
  • Research related to workplace productivity, absenteeism, and/or presenteism
  • Research increasing knowledge on metabolic/pharmacokinetic issues of pharmacological treatment in patients suffering from major depressive disorder (e.g. drug-drug interactions, dysfunctions, etc.)
  • Further understand the cognitive benefits of pharmacotherapy in major depressive disorders and other co-morbid conditions
  • Research increasing the knowledge on brain imaging and biomarkers in major depressive disorders
  • Exploring the special population needs in the pharmacological treatment of major depressive disorders (e.g. geriatric patients, severe depression, etc.)
  • Research relating to knowledge translation in major depressive disorders to primary care

About funding: This award (grant) is up to $100,000. Award funds are intended to be operating grants and must contribute towards the direct costs of the research program or project for which the funds are granted. Please note that the budget must be inclusive of institutional overhead where applicable; this amount shall not exceed 20% of the grant application budget. Please note that applicants may not receive a salary, a stipend, or an honorarium from the Pfizer Psychiatry Research Award.